US equities
|
AMD
$506.81
▲+4.73%
AMZN
$269.20
▲+7.38%
NVDA
$205.25
▼-0.70%
SPCX
$137.58
▼-2.64%
AAPL
$349.77
▲+5.38%
TSLA
$383.24
▼-3.83%
MU
$846.63
▼-0.99%
META
$631.18
▲+1.64%
AMD
$506.81
▲+4.73%
AMZN
$269.20
▲+7.38%
NVDA
$205.25
▼-0.70%
SPCX
$137.58
▼-2.64%
AAPL
$349.77
▲+5.38%
TSLA
$383.24
▼-3.83%
MU
$846.63
▼-0.99%
META
$631.18
▲+1.64%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Ardelyx, Inc. - Common Stock
(NQ:
ARDX
)
3.290
+0.260 (+8.58%)
Delayed Quote
Updated: 9:45 AM EST, Nov 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ardelyx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
April 01, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
March 12, 2026
Award recognizes leading chronic kidney disease advocates
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
March 09, 2026
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Inc (NASDAQ:ARDX) Reports Q4 2025 Revenue Beat but EPS Miss, Shares Fall
↗
February 19, 2026
Via
Chartmill
Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance
↗
January 09, 2026
Via
Stocktwits
Ardelyx Stock Slips After-Hours As $100M Shelf Filing Sparks Dilution Fears After Strong Q3
↗
November 04, 2025
Via
Stocktwits
Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela
↗
October 31, 2025
Via
Stocktwits
Ardelyx to Participate in Upcoming Investor Conferences
March 04, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership
↗
March 01, 2026
Ardelyx is coming off a strong Q4 earnings report for fiscal year 2025. But how is the stock performing?
Via
The Motley Fool
Topics
Regulatory Compliance
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
February 24, 2026
First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrow
From
Ardelyx, Inc.
Via
GlobeNewswire
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug
↗
February 24, 2026
On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.
Via
Stocktwits
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today
↗
February 23, 2026
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Government
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?
↗
February 20, 2026
Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.
Via
Stocktwits
Topics
Earnings
Intellectual Property
ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time
↗
February 19, 2026
The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share.
Via
Stocktwits
Topics
Artificial Intelligence
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 19, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
February 05, 2026
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Receives New Patent for Tenapanor
February 03, 2026
New patent covers IBSRELA® and XPHOZAH® and expires in 2042
From
Ardelyx, Inc.
Via
GlobeNewswire
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 28, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
January 23, 2026
Issued on behalf of Avant Technologies Inc.
From
Equity Insider
Via
GlobeNewswire
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish?
↗
January 08, 2026
The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue.
Via
Stocktwits
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
January 08, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx (ARDX) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Ardelyx (ARDX) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake?
↗
November 19, 2025
The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock.
Via
The Motley Fool
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
November 07, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
November 05, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
November 04, 2025
Via
Benzinga
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
November 04, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
↗
November 04, 2025
Via
Benzinga
Cloudflare Posts Upbeat Q3 Results, Joins Amazon, Roku, Coinbase, Atlassian And Other Big Stocks Moving Higher On Friday
↗
October 31, 2025
Via
Benzinga
Discover the top movers in Friday's pre-market session.
↗
October 31, 2025
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
